Valuation: Colinz Laboratories Limited

Market Cap 112M 1.17M 1.01M 951K 865K 1.63M 1.65M 11.15M 4.36M 56.14M 4.4M 4.31M 187M P/E 2024
19.5x
P/E 2025 36.8x
Enterprise Value 63.01M 659K 569K 535K 486K 914K 929K 6.27M 2.45M 31.55M 2.47M 2.42M 105M EV / Sales 2024
0.43x
EV / Sales 2025 2.04x
Free-Float
31.44%
Yield 2024 *
-
Yield 2025 -
07-30 Colinz Laboratories Limited Reports Earnings Results for the First Quarter Ended June 30, 2026 CI
06-17 Annjana Dugar, Likhitta Dugar and Antariksh Dugar executed of Share Purchase Agreement to acquire an additional 34.56% stake in Colinz Laboratories Limited from Vijaya Mani for INR 43.5 million, CI
06-17 Annjana Dugar, Likhitta Dugar and Antariksh Dugar proposed to acquire an additional 26% stake in Colinz Laboratories Limited for INR 35.4 million. CI
05-25 Padam Dugar, Annjana Dugar, Likhitta Dugar and Antariksh Dugar acquired 15.01% stake in Colinz Laboratories Limited. CI
04-29 Colinz Laboratories Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2026 CI
01-24 Colinz Laboratories Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2025 CI
01-16 Hilsun Foods And Drugs Private Limited signed a letter of intent to acquire Factory Building, Factory Machinery, & Factory Land of Colinz Laboratories Limited for INR 40 million. CI
11-27 Colinz Laboratories Limited Appoints Falguni Kumawat as Company Secretary and Compliance Officer, with Effect from 1 December, 2025 CI
11-08 Colinz Laboratories Limited Announces of Demise Dr. Mani L.S., Founder Director, Company Secretary and Compliance Officer on 7 November 2025 CI
11-03 Colinz Laboratories Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2025 CI
25-07-31 Colinz Laboratories Limited Reports Earnings Results for the First Quarter Ended June 30, 2025 CI
25-05-21 Colinz Laboratories Limited Appoints Swapnil Jayesh Madiyar as Additional Director, Effective from May 16, 2025 CI
25-05-16 Colinz Laboratories Limited Reports Earnings Results for the Full Year Ended March 31, 2025 CI
1 day-4.06%
1 week-4.23%
Current month-2.60%
1 month+7.66%
3 months+75.54%
6 months+58.85%
Current year+48.93%
1 week 76.15
Extreme 76.15
84.5
1 month 74.1
Extreme 74.1
85.99
Current year 39.31
Extreme 39.31
87.91
1 year 36.11
Extreme 36.11
87.91
3 years 35.2
Extreme 35.2
88.7
5 years 15.55
Extreme 15.55
88.7
10 years 4.8
Extreme 4.8
88.7
Manager TitleAgeSince
Chief Executive Officer 74 -
Director of Finance/CFO - 2019-05-19
Compliance Officer - 2025-11-30
Director TitleAgeSince
Director/Board Member 74 1990-11-25
Director/Board Member 33 2024-08-07
Director/Board Member 76 2024-08-07
Change 5-day change 1-year change 3-year change Capi.($)
-4.06%-4.23%+84.54%+116.39% 2.2M
-0.10%-0.77%+17.58%+70.16% 48.57B
-3.26%-5.31%+53.19%+117.23% 40.99B
-0.60%-0.94%-7.29%+17.35% 12.35B
-2.75%+1.88%+14.81%+76.92% 12.2B
-0.19%-0.38%+30.40%+135.91% 9.08B
+1.56%+5.52%+23.46%+39.78% 7.41B
+0.52%+2.08%+40.75%-12.45% 7.13B
-0.07%+1.72%+13.39%+190.65% 6.86B
-2.51%-3.14%-27.46%+24.20% 5.92B
Average -1.15%+1.51%+24.34%+77.61% 15.05B
Weighted average by Cap. -1.20%+1.03%+25.21%+81.44%

Financials

2024 2025
Net sales 70.3M 735K 635K 597K 543K 1.02M 1.04M 6.99M 2.73M 35.2M 2.76M 2.7M 117M 65.28M 683K 590K 554K 504K 947K 963K 6.49M 2.54M 32.69M 2.56M 2.51M 109M
Net income 4.87M 50.9K 43.96K 41.31K 37.57K 70.63K 71.8K 484K 189K 2.44M 191K 187K 8.1M 4.97M 51.93K 44.85K 42.15K 38.33K 72.07K 73.26K 494K 193K 2.49M 195K 191K 8.26M
Net Debt -64.3M -672K -581K -546K -496K -933K -949K -6.39M -2.5M -32.2M -2.52M -2.47M -107M -49.09M -513K -443K -417K -379K -712K -724K -4.88M -1.91M -24.58M -1.93M -1.89M -81.7M
Logo Colinz Laboratories Limited
Colinz Laboratories Ltd. is an India-based company that is engaged in the manufacturing and marketing of pharmaceutical formulations, particularly in the gynecological sector. It is engaged in the manufacturing and marketing various allopathic, ayurvedic, and nutraceuticals pharmaceutical formulations in the dosage forms of tablets, capsules, liquid orals and ointments, among others. The company has specialized products for Gynecology, cardiology, gastroenterology, and others. Its oncology products include imitinib, erlotinib, letrozole, exemestane, bortezomib, fludarabine phosphate, and doxorubicin. Its Ayurvedic products include anti-diarrhoeals, anti-pyretics, anti-inflammatories, anti-spasmodics, cough syrups, appetite stimulating agents, and memory boosters. Its nutraceuticals products include spirulina tabs/caps, spirulina with vitamins & minerals, omega 3 fatty acid caps in softgel, codliver oil with vitamin caps in soft gel, collagen, and glucosamine & chondroitin tabs.
Employees
65
Date Price Change Volume
26-08-14 ₹79.87 -4.06% 309
26-08-13 ₹83.25 +2.15% 2,500
26-08-12 ₹81.50 +2.28% 15,244
26-08-11 ₹79.68 +0.01% 246
26-08-10 ₹79.67 -4.47% 756
  1. Stock Market
  2. Stocks
  3. COLINZ6 Stock